source
- Novartis CEO says AI could cut drug development time and boost success ratesAt an investor event in London, Novartis chief executive Vas Narasimhan, who also sits on the board of AI company Anthropic, explained how the Swiss drugmaker is turning to artificial intelligence…
- Congressional biotech panel cautions on rising China licensing dealsA bipartisan congressional commission that advises on U.S. biotech competitiveness is concluding its work with a focus on partnerships with Chinese firms. The panel highlighted the growing number…